NCT07123090
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07123090
Title A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (SPARCC)
Acronym SPARCC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stephanie Berg
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.